Gyre Therapeutics, Inc. (GYRE)
6.70
+0.01
(+0.15%)
USD |
NASDAQ |
Sep 16, 16:00
6.70
0.00 (0.00%)
After-Hours: 18:32
Gyre Therapeutics Shareholders Equity (Quarterly) : 130.36M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 130.36M |
| March 31, 2026 | 101.31M |
| December 31, 2025 | 106.03M |
| September 30, 2025 | 101.92M |
| June 30, 2025 | 92.03M |
| March 31, 2025 | 68.12M |
| December 31, 2024 | 63.32M |
| September 30, 2024 | 63.18M |
| June 30, 2024 | 60.35M |
| March 31, 2024 | 56.64M |
| December 31, 2023 | 48.70M |
| September 30, 2023 | 3.517M |
| June 30, 2023 | 4.995M |
| March 31, 2023 | 7.356M |
| December 31, 2022 | 42.52M |
| September 30, 2022 | 29.38M |
| June 30, 2022 | 79.06M |
| March 31, 2022 | 27.08M |
| December 31, 2021 | 41.09M |
| September 30, 2021 | 60.74M |
| June 30, 2021 | 85.16M |
| March 31, 2021 | 104.09M |
| December 31, 2020 | 76.07M |
| September 30, 2020 | 94.06M |
| June 30, 2020 | 108.96M |
| Date | Value |
|---|---|
| March 31, 2020 | 97.52M |
| December 31, 2019 | 68.34M |
| September 30, 2019 | 81.27M |
| June 30, 2019 | 93.11M |
| March 31, 2019 | 105.81M |
| December 31, 2018 | 119.94M |
| September 30, 2018 | 129.95M |
| June 30, 2018 | 136.96M |
| March 31, 2018 | 142.85M |
| December 31, 2017 | 30.77M |
| September 30, 2017 | 24.88M |
| June 30, 2017 | 30.35M |
| March 31, 2017 | 13.84M |
| December 31, 2016 | 16.07M |
| September 30, 2016 | 19.60M |
| June 30, 2016 | 23.48M |
| March 31, 2016 | 27.99M |
| December 31, 2015 | 31.42M |
| September 30, 2015 | 36.21M |
| June 30, 2015 | 99.53M |
| March 31, 2015 | 103.23M |
| December 31, 2014 | -0.475M |
| September 30, 2014 | 112.91M |
| June 30, 2014 | 117.02M |
| March 31, 2014 | 124.10M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Cytokinetics, Inc. | -173.49M |
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 199.26M |
| Total Liabilities (Quarterly) | 33.51M |
| Debt to Equity Ratio | 0.0262 |
| Current Ratio | 4.259 |
| Net Debt Paydown Yield | -0.05% |